WALTZ Gain CE Certificate

21 February 2014- WALTZ CoCr Coronary Stent System ("WALTZ"), independently developed by Shanghai MicroPort Medical (Group) Co., Ltd, gained CE certificate.
WALTZ CoCr Coronary Stent System is the platform for FireBird2 Rapamycin eluting coronary stent system and is designed for the treatment of ischemic heart disease. It consists of a L605 cobalt-based alloy stent and a delivery system. Mr. Zhirong Tang, Vice President of Coronary R&D, stated, "With competitive operational performance, WALTZ should be an excellent option for patients who are suitable for bare metal stent."
The CE approval provides preconditions for WALTZ to penetrate most international markets.